- Author:
Jianwei ZHENG
1
;
Junfeng WANG
2
;
Qian WANG
1
;
Hongye ZOU
3
;
Hong WANG
1
;
Zhenhua ZHANG
1
;
Jianghe CHEN
1
;
Qianqian WANG
1
;
Panxia WANG
1
;
Yueshan ZHAO
1
;
Jing LU
1
;
Xiaolei ZHANG
1
;
Songtao XIANG
4
;
Haibin WANG
5
;
Jinping LEI
1
;
Hong-Wu CHEN
3
;
Peiqing LIU
1
;
Yonghong LIU
2
;
Fanghai HAN
6
;
Junjian WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Antagonist; Castration-resistant prostate cancer; Elaiophylin; Nuclear receptor; RORγ
- From: Acta Pharmaceutica Sinica B 2020;10(12):2313-2322
- CountryChina
- Language:English
- Abstract: Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor ROR